Pfizer
PFE
3,103 hedge funds and large institutions have $162B invested in Pfizer in 2023 Q1 according to their latest regulatory filings, with 139 funds opening new positions, 1,374 increasing their positions, 1,314 reducing their positions, and 232 closing their positions.
5% more repeat investments, than reductions
Existing positions increased: 1,374 | Existing positions reduced: 1,314
0.23% more ownership
Funds ownership: 69.7% → 69.93% (+0.23%)
5% less funds holding
Funds holding: 3,266 → 3,103 (-163)
20% less capital invested
Capital invested by funds: $202B → $162B (-$40.8B)
25% less call options, than puts
Call options by funds: $1.56B | Put options by funds: $2.08B
40% less first-time investments, than exits
New positions opened: 139 | Existing positions closed: 232
59% less funds holding in top 10
Funds holding in top 10: 193 → 80 (-113)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$847M |
| 2 |
Renaissance Technologies
New York
|
+$478M |
| 3 |
Charles Schwab
San Francisco,
California
|
+$456M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$292M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$290M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$1.06B |
| 2 |
JP Morgan Chase
New York
|
-$578M |
| 3 |
Barclays
London,
United Kingdom
|
-$257M |
| 4 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$226M |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$216M |
PFE Hedge Fund Activity: Q1 2023 in Review
3,103 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q1 2023, worth a combined $162B — down 20% from $202B a quarter earlier.
Sellers outnumbered buyers: 232 funds closed out of PFE and 139 opened new positions — a net loss of 93 holders — while 1,314 trimmed existing stakes and 1,374 added.
The largest buyer was Wellington Management Group, adding an estimated $847M. The largest seller was Capital World Investors, cutting an estimated $1.06B.
- 3,103 institutional investors held Pfizer (PFE) as of Q1 2023, down from 3,266 in Q4 2022.
- Funds reported $162B of Pfizer stock for Q1 2023, down 20% quarter-over-quarter.
- 139 funds opened new Pfizer positions in Q1 2023 and 232 closed out, a net change of -93 holders.
- The largest Pfizer buyer in Q1 2023 was Wellington Management Group, an estimated $847M added.
- The largest Pfizer seller in Q1 2023 was Capital World Investors, an estimated $1.06B sold.
Based on aggregated 13F filings for Q1 2023.